Skip Navigation

NCAC-SOT Fall Webinar: Looking Forward After 19 Years of the Endocrine Disruptor Screening Program

Friday, September 18, 2015, 9:00 AM–12:00 Noon EDT

In the 1990s, a variety of chemicals were suspected of disrupting the endocrine system in animals. Based on scientific evidence, Congress approved the Food Quality Protection Act and Safe Drinking Water Act (SDWA) Amendments in August 1996 requiring the US EPA to initiate the Endocrine Disruptor Screening Program (EDSP) to screen pesticides, commercial chemicals and environmental contaminants for their potential effect on the endocrine systems of humans and wildlife. EDSP is a two-tiered screening process aimed at identifying chemicals and determining their potential to disrupt the endocrine systems of mammals, birds and fish.

Tier 1: US EPA will identify chemicals that have the potential to interact with the endocrine system.

Tier 2: US EPA will determine the endocrine-related effects caused by each chemical and obtain information about effects at various doses to enable subsequent risk assessments for each chemical.
US EPA announced the initial list of chemicals to be screened for their potential effects on the endocrine system (or Tier 1 testing) on April 15, 2009, and in November 2010, EPA issued a finalist (“List 1”) of chemicals for screening as well as draft policies and procedures for the EDSP. The second list of chemicals (as well as related policies and procedures) for screening under the SDWA (“List 2”) was issued on June 14, 2013 (with minor revisions in May 2014); however, US EPA currently does not have authorization from the White House Office of Management and Budget (OMB) to collect these data. On June 18, 2015, US EPA announced a plan for incorporating validated high-throughput assays and a computational model into the EDSP to screen chemicals for their ability to interact with the endocrine system. This proposed new method would serve as an alternative for three of the eleven current assays in the EDSP Tier 1 screening battery (estrogen receptor binding, estrogen receptor transactivation, uterotrophic). On July 30, 2015, US EPA released its reviews of the Tier 1 screening assay results for the first 52 pesticide chemicals (active and inert ingredients) in the EDSP, representing a major milestone of achievement for the almost 20-year-old program
This webinar provides a great opportunity to hear about the current status of the EDSP program from stakeholders involved with the program as well different perspectives on the future directions of the program.
9:00 AM–9:05 AM Welcome/Procedures and Housekeeping Remarks
9:05 AM–9:30 AM Nineteen Years of the Endocrine Disruptor Screening Program: Where We Started and Where We Are Heading
David J. Dix, PhD, Office of Science Coordination and Policy (OSCP), US EPA
9:30 AM–10:00 AM Using High-Throughput Assays and Computational Tools for Endocrine Screening
Patience Browne, PhD, Office of Science Coordination and Policy (OSCP), US EPA
10:00 AM–10:30 AM Challenges and Opportunities for Wildlife Testing
Caren Helbing, PhD, Professor Department of Biochemistry and Microbiology, University of Victoria, British Columbia, Canada
10:30 AM–11:00 AM Concepts of Endocrinology: Issues Relevant to Endocrine Disruptor Screening
Raphael Witorsch, PhD, Professor Emeritus Medical College of Virginia VCU and Consultant
11:00 AM–11:30 AM Round Table Presentations—Application of Tox21/ToxCast and the Future of Regulatory Decision Making
Industry Perspective: A Framework for Building Scientific Confidence in Tox21 and Risk21 Methods 
Rick Becker, PhD, DABT, Senior Toxicologist American Chemistry Council 
Academic Perspective: The Need for Evidence-Based Approaches 
Thomas Hartung, MD, Director Center for Alternatives to Animal Testing (CAAT), Johns Hopkins University Bloomberg School of Public Health 
Government Perspective: The Importance of Fit-for-Purpose Validation 
Warren Casey, PhD, Director at National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods (NTP/NICEATM) 
11:30 AM–12:00 Noon Round Table Discussion—Application of Tox21/ToxCast and the Future of Regulatory Decision Making
All Speakers
12:00 Noon Closing Remarks

New ALTEX: 2/2018

ALTEX cover 51

Support ALTWEB, Make a Gift
Online Humane Science Course


Building a Better Epithelium: New Frontiers in 3D Conference
April 25, 2019
Cambridge, MA

CellTox 2019
May 7, 2019
Milano, Italy

Biosystems Engineering: Bioreactors and Cell Factories
May 12-17, 2019
Braunweld, Switzerland

ALTERTOX Academy Training:
In Vitro Exposure Systems and Dosimetry Assessment Tools for Inhalation Toxicology
May 23-24, 2019
Neuchatel, Switzerland

6th Symposium on Social Housing of Laboratory Animals
June 3-4, 2019
Beltsville, Maryland

Society for In Vitro Biology Annual Meeting
June 8-12, 2019
Tampa, Florida

Upcoming: CAAT-Europe Information Day On Biology-inspired Microphysiological Systems (MPS) to Advance Medicines for Patients' Benefit
June 17, 2019
Berlin, Germany

ALTERTOX Academy Training:
PBPK Modeling and Quantitative In Vitro-In Vivo Extrapolation
October 3-4, 2019
Wageningen, Netherlands

ALTERTOX Academy Training:
Novel In Silico Models for Assessment of Cosmetics
October 17-18, 2019
Milan, Italy

ALTERTOX Academy Training:
In Vitro Lung Models
November 14-15, 2019
Geneva, Switzerland

Save the Date!
5th International Conference on Alternatives for Developmental Neurotoxicity (DNT) Testing
February 3-5, 2020
Konstanz, Germany

Full Listing of CAAT Programs
and Activities